Eptifibatide Acetate Clinical Trials

Size	Price	Qty
50mg	USD 180

Clinical Trials

Eptifibatide Acetate has been evaluated in numerous clinical trials investigating its efficacy across various cardiovascular and cerebrovascular disorders, including myocardial infarction, acute coronary syndrome, coronary artery disease, and acute ischemic stroke, as well as severe pneumonia. These investigations span Phase 1 through Phase 4 clinical studies sponsored by academic institutions, research foundations, and government organizations, such as the Ottawa Heart Institute Research Corporation, the University of Alabama at Birmingham, and the Ministry of Science and Technology of the People's Republic of China. Several trials, including NCT00251823 assessing eptifibatide-facilitated percutaneous coronary intervention and NCT02925923 examining antiplatelet strategies in troponin-negative acute coronary syndrome, have reached completed status. Additional studies maintain terminated or unknown recruitment statuses while exploring adjunctive intracoronary and endovascular interventions.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07347626	NOT_YET_RECRUITING	Acute Ischemic Stroke	Xinqiao Hospital of Chongqing	2026-03-01	PHASE3
NCT03735979	COMPLETED	Acute Ischemic Stroke	Washington University School of Medicine	2019-10-15	PHASE3
NCT03844594	UNKNOWN	Acute Ischemic Stroke	Ministry of Science and Technology of the People´s Republic of China	2019-04-06	PHASE3
NCT01522417	COMPLETED	Myocardial Infarction; Acute Coronary Syndromes; Unstable Angina	Medicure	2012-04	PHASE2
NCT02925923	COMPLETED	Acute Coronary Syndrome; Angina, Unstable	University of Alabama at Birmingham	2016-11-01	PHASE2
NCT02204852	COMPLETED	Septic Shock	Sisse R. Ostrowski, MD PhD DMSc	2014-09	PHASE2
NCT01919723	COMPLETED	Acute Coronary Syndrome	University of Alabama at Birmingham	2014-02	PHASE2
NCT01977456	COMPLETED	Stroke; Brain Infarction	Arthur Pancioli	2013-09	PHASE2
NCT01532544	TERMINATED	Pneumonia	Thrombologic ApS	2012-06	PHASE2
NCT01076764	COMPLETED	Acute Coronary Syndrome	Sanofi	2010-04	PHASE3
NCT00894803	COMPLETED	Ischemic Stroke; Stroke; Brain Infarction	University of Cincinnati	2009-07	PHASE2
NCT00834899	TERMINATED	Sickle Cell Disease	University of North Carolina, Chapel Hill	2009-01	PHASE1; PHASE2
NCT01863134	COMPLETED	Non ST Elevation Myocardial Infarction	Medical University of Silesia	2005-01	PHASE4
NCT00812435	TERMINATED	Myocardial Infarction	Medstar Health Research Institute	2007-08	PHASE3
NCT00638976	COMPLETED	Cardiovascular Disease	Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS	2007-11	PHASE3
NCT00945308	UNKNOWN	Acute Myocardial Infarction	Assaf-Harofeh Medical Center	2009-08	PHASE2
NCT00061373	COMPLETED	Ischemic Stroke	National Institute of Neurological Disorders and Stroke (NINDS)	2003-05	PHASE2
NCT01454440	TERMINATED	Coronary Artery Disease	University of Turin, Italy	2007-10	PHASE4
NCT00089895	COMPLETED	Myocardial Ischemia; Acute Coronary Syndrome	Organon and Co	2004-11-01	PHASE3
NCT00719914	TERMINATED	ST-Elevation Myocardial Infarction	Brigham and Women's Hospital	2007-11	PHASE2
NCT00317395	COMPLETED	Coronary Disease	Sanofi	2006-06	PHASE2
NCT00426751	COMPLETED	Infarction, Myocardial	GlaxoSmithKline	2006-10	PHASE3
NCT00111566	COMPLETED	Coronary Artery Disease; Myocardial Infarction	Cardiology Research UBC	2004-12	PHASE4
NCT00251823	COMPLETED	Myocardial Infarction	Ottawa Heart Institute Research Corporation	2005-07	PHASE3
NCT00370045	UNKNOWN	Coronary Artery Disease	LifeBridge Health	2006-03	PHASE4
NCT00289601	TERMINATED	Angioplasty	Brigham and Women's Hospital	2006-03	PHASE4
NCT00250991	COMPLETED	Stroke	University of Cincinnati	2003-07	PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-01-16)

Check the Eptifibatide Acetate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Eptifibatide Acetate selectively binds to the platelet membrane glycoprotein IIb/IIIa receptor, reversibly inhibiting the binding of fibrinogen and von Willebrand factor to block inter-platelet cross-linking. This targeted inhibition prevents platelet aggregation and thrombus formation, thereby reducing ischemic complications in clinical settings such as acute coronary syndrome, myocardial infarction, and ischemic stroke.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).